Cambridge: AstraZeneca has announced that Fasenra (benralizumab) has been approved in the European Union (EU) as an add-on treatment for adult patients with relapsing or refractory ...

AstraZeneca’s Fasenra (benralizumab) has been approved in the European Union (EU) as an add-on treatment for adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis ...

The European Commission (EC) has approved AstraZeneca's Fasenra (benralizumab) as an add-on therapy for adults with relapsing ...

It can now also be used as an add-on treatment in adults with relapsing or refractory eosinophilic granulomatosis with polyangiitis (EGPA). Its original indication is as an add-on maintenance ...

As AstraZeneca builds up indications for Fasenra, an ongoing trial will determine whether the respiratory drug can make up ...

The new treatment will be a competitor of GSK’s Nucala (mepolizumab), which was approved in 2018 as the first targeted ...

AstraZeneca’s drug Fasenra gets an expanded indication in the EU and is now approved as a treatment for the rare autoimmune disease known as Churg-Strauss syndrome.

eosinophilic granulomatosis with polyangiitis (EGPA), and hypereosinophilic syndrome (HES), and has also shown efficacy in a phase 3 trial in chronic obstructive pulmonary disease (COPD).

eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome. The drug remains one of GSK's top products, with sales of £856 million ($1.1 billion) in the first half of this year ...